Mesothelioma.com Resources for Patients and their Families

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

Brief Summary

The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.

Tracking Information
First Received DateMarch 23, 2009
Last Changed DateDecember 1, 2014
Start DateJanuary 2009
Actual Primary Completion DateDecember 2011
Primary Outcome Measures

Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line [Time Frame: one year]

Secondary Outcome Measures

Evaluate retrospectively the correlation between gene expression and polymorphisms in candidate genes and array-CGH data, immunohistochemistry data, and clinical data. [Time Frame: one year]

Descriptive Information
PhaseN/A
Study TypeObservational
Condition
  • MALIGNANT PLEURAL MESOTHELIOMA
Study Arms / Comparison Groups0 / 1
Detailed Description

Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor prognosis. The combination of cisplatin and pemetrexed has recently become the standard of care in the first-line treatment of MPM. For patients who are unfit to receive a cisplatin-based chemotherapy, pemetrexed alone [7] or combined with carboplatin [8] has been proposed as an alternative treatment choice. The identification of molecular predictors of effective therapy is important for maximizing therapeutic efficacy and minimizing useless treatment in cancer patients.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment121
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- MPM diagnosis

- Availability of tumor tissue to perform analysis

Exclusion Criteria :

- Other primary diagnosis

- No archival tissue available

Administrative Information
NCTIDNCT00867711
Responsible Party,
SponsorIstituto Clinico Humanitas
Verification DateNovember 2014
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Talcum Powder Lawsuits: How Asbestos-Contaminated Talc Harms People

The Benefits of Comprehensive Support Services for Mesothelioma Families

High Cost of Asbestos Abatement Leaves Lower Income Communities at Risk

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: